Drugs / CD123-CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05574608 | Oct 2022 → Oct 2023 | acute myeloid leukemia | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123-CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574608 ↗ |
| Modality | Cell therapy | “CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.” NCT05574608 ↗ |
| Route | Other | “allogenic CD123-Targeted CAR-NK cells infusion” NCT05574608 ↗ |